Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]
Drug-Device Combinations
Canada approves Abbott Freestyle Libre 2 for adults and children
Abbott (NYSE:ABT) announced that Health Canada has approved its FreeStyle Libre 2 continuous glucose monitor for adults and children. The next-generation, wearable, sensor-based CGM technology with real-time alarms is approved for use in adults and children (four years old and up) and will be priced the same as the current FreeStyle Libre system, according to a […]
BD to put $1.2B into drug-delivery plant expansions
Becton Dickinson (NYSE:BDX) announced today that it plans to invest $1.2 billion to expand and upgrade multiple drug-delivery facilities. Franklin Lakes, N.J.-based BD plans to invest the $1.2 billion over a four-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug-delivery systems (ADDS) across its six global manufacturing locations, […]
Appeals court nixes GSK’s petition for new trial in Vectura patent spat
The Federal Circuit Court has rejected Glaxo Smith Kline’s (NYSE:GSK) petition for a new trial in a patent case brought by British inhaler company Vectura. The circuit court upheld a May 2019 jury verdict in U.S. District Court for the District of Delaware, awarding Ventura $89.7 million damages for the period from August 2016 through […]
Lilly and Ypsomed team up on automated insulin delivery
Eli Lilly (NYSE:LLY) and Ypsomed (SWX:YPSN) are teaming up to create an automated insulin delivery system. Lilly would commercialize the device, which would incorporate an insulin pump from Ypsomed. Burgdorf, Switzerland-based Ypsomed launched its Mylife YpsoPump in Europe in 2016. Now available in 21 countries, the pump includes a touch screen. Lilly plans on commercializing […]
Alaris remediation could cost BD up to $244M
Becton Dickinson (NYSE:BDX) in its most recent fiscal year set aside $244 million to cover future product remediation costs, including the company’s work to fix its problematic Alaris infusion pumps. The Franklin Lakes, N.J.–based company has had shipments of the pumps on hold since early this year, when FDA called for a comprehensive 510(k) submission to […]
Brooklyn spending $500K on BioBAT research and manufacturing space
SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Brooklyn Borough President Eric Adams awarded the grant to SUNY to construct a state-of-the-art biotechnology research and manufacturing space at BioBAT, a nonprofit organization seeking to grow the biotechnology industry in New York City. […]
Baxter lands major DoD contract
The U.S. Defense Dept. (DoD) announced that it awarded Baxter (NYSE:BAX) $40 million for its infusion pumps and accessories. Baxter’s contract includes a maximum $40 million fixed-price award with economic-price-adjustment and indefinite-delivery/indefinite-quantity for its infusion pumps and accessories. The competitive acquisition had 105 offers received. The five-year contract has no option periods with the location being […]
Baxter wins Canadian clearance for infusion system
Baxter (NYSE:BAX) Canada announced today that it received Health Canada authorization for its Novum IQ infusion platform. Novum IQ received marketing authorization for its large volume pump and syringe infusion pumps, as well as Mississauga, Ontario-based Baxter Canada’s Dose IQ safety software. Baxter expects Novum IQ to be available to Canadian customers in the coming weeks, […]
Teva Pharmaceuticals’ stock sinks 6.5% on Q3 results
Teva (NYSE: TEVA) reported third-quarter results today that matched analysts’ consensus forecast. The company will maintain its guidance for the rest of the year. Teva, which has dual headquarters in Israel and Parsippany, N.J., reported a loss of -$4.3 billion or -$3.97 per share on revenue of $3.9 billion for the quarter ended September 30, […]
